Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics

Karina M. Berg, Jennifer Mouriz, Xuan Li, Elise Duggan, Uri Goldberg, Julia H. Arnsten

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Directly observed therapy (DOT) programs for HIV treatment have demonstrated feasibility, acceptability, and improved viral suppression, but few have been rigorously tested. We describe a randomized controlled trial testing the efficacy of an antiretroviral DOT program in methadone maintenance clinics. Our objective was to determine if DOT is more efficacious than self-administered antiretroviral therapy for reducing HIV viral load, improving adherence, and reducing drug resistance among opioid dependent drug users receiving methadone treatment. Methods: Participants were randomized to treatment as usual (TAU) or antiretroviral DOT for the 24-week intervention. TAU participants received standard adherence counseling, and DOT participants received standard adherence counseling plus directly observed antiretroviral therapy, which was delivered at the same time as they received daily methadone. Assessments occurred at baseline, weekly for 8 weeks, and then monthly for 4 months. Our primary outcomes were between-group changes from baseline to the end of the intervention in: HIV viral load, antiretroviral adherence, and number of viral mutations. Results: Between June 2004 and August 2007, we screened 3231 methadone-maintained patients and enrolled 77; 39 participants were randomized to DOT and 38 to TAU. 65 completed the 24-week intervention. Conclusions: Our trial will allow rigorous evaluation of the efficacy of directly observed antiretroviral therapy delivered in methadone clinics for improving adherence and clinical outcomes. This detailed description of trial methodology can serve as a template for the development of future DOT programs and can guide protocols for studies among HIV-infected drug users receiving methadone for opioid dependence.

Original languageEnglish (US)
Pages (from-to)481-489
Number of pages9
JournalContemporary Clinical Trials
Volume30
Issue number5
DOIs
StatePublished - Sep 2009

Fingerprint

Directly Observed Therapy
Methadone
Randomized Controlled Trials
HIV
Drug Users
Viral Load
Opioid Analgesics
Counseling
Therapeutics
Drug Resistance

Keywords

  • Antiretroviral therapy
  • Directly observed therapy
  • HIV
  • Medication adherence
  • Methadone
  • Randomized trial
  • Substance abuse treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics. / Berg, Karina M.; Mouriz, Jennifer; Li, Xuan; Duggan, Elise; Goldberg, Uri; Arnsten, Julia H.

In: Contemporary Clinical Trials, Vol. 30, No. 5, 09.2009, p. 481-489.

Research output: Contribution to journalArticle

@article{0802927a03864a7ab906a21524a9bfd4,
title = "Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics",
abstract = "Background: Directly observed therapy (DOT) programs for HIV treatment have demonstrated feasibility, acceptability, and improved viral suppression, but few have been rigorously tested. We describe a randomized controlled trial testing the efficacy of an antiretroviral DOT program in methadone maintenance clinics. Our objective was to determine if DOT is more efficacious than self-administered antiretroviral therapy for reducing HIV viral load, improving adherence, and reducing drug resistance among opioid dependent drug users receiving methadone treatment. Methods: Participants were randomized to treatment as usual (TAU) or antiretroviral DOT for the 24-week intervention. TAU participants received standard adherence counseling, and DOT participants received standard adherence counseling plus directly observed antiretroviral therapy, which was delivered at the same time as they received daily methadone. Assessments occurred at baseline, weekly for 8 weeks, and then monthly for 4 months. Our primary outcomes were between-group changes from baseline to the end of the intervention in: HIV viral load, antiretroviral adherence, and number of viral mutations. Results: Between June 2004 and August 2007, we screened 3231 methadone-maintained patients and enrolled 77; 39 participants were randomized to DOT and 38 to TAU. 65 completed the 24-week intervention. Conclusions: Our trial will allow rigorous evaluation of the efficacy of directly observed antiretroviral therapy delivered in methadone clinics for improving adherence and clinical outcomes. This detailed description of trial methodology can serve as a template for the development of future DOT programs and can guide protocols for studies among HIV-infected drug users receiving methadone for opioid dependence.",
keywords = "Antiretroviral therapy, Directly observed therapy, HIV, Medication adherence, Methadone, Randomized trial, Substance abuse treatment",
author = "Berg, {Karina M.} and Jennifer Mouriz and Xuan Li and Elise Duggan and Uri Goldberg and Arnsten, {Julia H.}",
year = "2009",
month = "9",
doi = "10.1016/j.cct.2009.05.003",
language = "English (US)",
volume = "30",
pages = "481--489",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics

AU - Berg, Karina M.

AU - Mouriz, Jennifer

AU - Li, Xuan

AU - Duggan, Elise

AU - Goldberg, Uri

AU - Arnsten, Julia H.

PY - 2009/9

Y1 - 2009/9

N2 - Background: Directly observed therapy (DOT) programs for HIV treatment have demonstrated feasibility, acceptability, and improved viral suppression, but few have been rigorously tested. We describe a randomized controlled trial testing the efficacy of an antiretroviral DOT program in methadone maintenance clinics. Our objective was to determine if DOT is more efficacious than self-administered antiretroviral therapy for reducing HIV viral load, improving adherence, and reducing drug resistance among opioid dependent drug users receiving methadone treatment. Methods: Participants were randomized to treatment as usual (TAU) or antiretroviral DOT for the 24-week intervention. TAU participants received standard adherence counseling, and DOT participants received standard adherence counseling plus directly observed antiretroviral therapy, which was delivered at the same time as they received daily methadone. Assessments occurred at baseline, weekly for 8 weeks, and then monthly for 4 months. Our primary outcomes were between-group changes from baseline to the end of the intervention in: HIV viral load, antiretroviral adherence, and number of viral mutations. Results: Between June 2004 and August 2007, we screened 3231 methadone-maintained patients and enrolled 77; 39 participants were randomized to DOT and 38 to TAU. 65 completed the 24-week intervention. Conclusions: Our trial will allow rigorous evaluation of the efficacy of directly observed antiretroviral therapy delivered in methadone clinics for improving adherence and clinical outcomes. This detailed description of trial methodology can serve as a template for the development of future DOT programs and can guide protocols for studies among HIV-infected drug users receiving methadone for opioid dependence.

AB - Background: Directly observed therapy (DOT) programs for HIV treatment have demonstrated feasibility, acceptability, and improved viral suppression, but few have been rigorously tested. We describe a randomized controlled trial testing the efficacy of an antiretroviral DOT program in methadone maintenance clinics. Our objective was to determine if DOT is more efficacious than self-administered antiretroviral therapy for reducing HIV viral load, improving adherence, and reducing drug resistance among opioid dependent drug users receiving methadone treatment. Methods: Participants were randomized to treatment as usual (TAU) or antiretroviral DOT for the 24-week intervention. TAU participants received standard adherence counseling, and DOT participants received standard adherence counseling plus directly observed antiretroviral therapy, which was delivered at the same time as they received daily methadone. Assessments occurred at baseline, weekly for 8 weeks, and then monthly for 4 months. Our primary outcomes were between-group changes from baseline to the end of the intervention in: HIV viral load, antiretroviral adherence, and number of viral mutations. Results: Between June 2004 and August 2007, we screened 3231 methadone-maintained patients and enrolled 77; 39 participants were randomized to DOT and 38 to TAU. 65 completed the 24-week intervention. Conclusions: Our trial will allow rigorous evaluation of the efficacy of directly observed antiretroviral therapy delivered in methadone clinics for improving adherence and clinical outcomes. This detailed description of trial methodology can serve as a template for the development of future DOT programs and can guide protocols for studies among HIV-infected drug users receiving methadone for opioid dependence.

KW - Antiretroviral therapy

KW - Directly observed therapy

KW - HIV

KW - Medication adherence

KW - Methadone

KW - Randomized trial

KW - Substance abuse treatment

UR - http://www.scopus.com/inward/record.url?scp=68349101321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349101321&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2009.05.003

DO - 10.1016/j.cct.2009.05.003

M3 - Article

VL - 30

SP - 481

EP - 489

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

IS - 5

ER -